Nanomedicine for overcoming therapeutic and diagnostic challenges associated with pancreatic cancer

Disha Iyengar; Katyayani Tatiparti; Navnath S Gavande; Samaresh Sau; Arun K Iyer

doi:10.1016/j.drudis.2022.02.026

Nanomedicine for overcoming therapeutic and diagnostic challenges associated with pancreatic cancer

Drug Discov Today. 2022 Jun;27(6):1554-1559. doi: 10.1016/j.drudis.2022.02.026. Epub 2022 Mar 2.

Authors

Disha Iyengar¹, Katyayani Tatiparti¹, Navnath S Gavande², Samaresh Sau³, Arun K Iyer⁴

Affiliations

¹ Use-inspired Biomaterials & Integrated Nano Delivery (U-BiND) Systems Laboratory, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA.
² Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA.
³ Use-inspired Biomaterials & Integrated Nano Delivery (U-BiND) Systems Laboratory, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA. Electronic address: samaresh.sau@wayne.edu.
⁴ Use-inspired Biomaterials & Integrated Nano Delivery (U-BiND) Systems Laboratory, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA; Molecular Imaging Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA. Electronic address: arun.iyer@wayne.edu.

PMID: 35247592
DOI: 10.1016/j.drudis.2022.02.026

Abstract

Pancreatic cancer is the second leading cause of cancer-related death in the USA. The 5-year survival rate for pancreatic cancer is as low as 10%, making it one of the most deadly cancers. This dismal prognosis is caused, in part, by the lack of early detection and screening options, leading to late-stage detection of the disease, at a point at which chemotherapy is no longer effective. However, nanoparticle (NP) drug delivery systems have increased the efficacy of chemotherapeutics by improving the targeting ability of drugs to the tumor site, while also decreasing the risk of local and systemic toxicity. Such efforts can contribute to the development of early diagnosis and routine screening tests, which will drastically improve the survival rates and prognosis of patients with pancreatic cancer.

Keywords: Early detection biomarkers; Early screening and diagnosis; Improved survival rate and prognosis; Nanoparticle drug delivery; Pancreatic cancer; Pathology.

Publication types

Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't

MeSH terms

Early Detection of Cancer
Humans
Nanomedicine*
Pancreatic Neoplasms* / diagnosis
Pancreatic Neoplasms* / drug therapy
Pharmaceutical Preparations

Substances

Pharmaceutical Preparations